28 Diarrhea was a risk factor for sub-therapeutic concentration of posaconazole in patients using tablets, but there was a decreasing trend observed in this effect. 47 , 48 Metoclopramide, which was retained in M5, 18 similar to the diarrhea limited the absorption and altered the exposure of posaconazole by increasing gastrointestinal motility.
1
—
—